While cisplatin and carboplatin are active versus most common cancers, epithelial
malignancies are incurable when metastatic. Even if an initial response occurs, acquired …

Abstract B-cell lymphoma 2 (BCL2) proteins are important cell death regulators, whose main
function is to control the release of cytochrome c from mitochondria in the intrinsic apoptotic …

One of the most effective ways to combat different types of cancer is through early diagnosis
and administration of effective treatment, followed by efficient monitoring that will allow …

Abstract The PI3K/AKT/mTOR pathway regulates cell growth and proliferation and is often
dysregulated in cancer due to mutation, amplification, deletion, methylation and post …

Metastatic disease is the most common mechanism of death in patients with advanced
bladder cancer. As for most solid tumors, chemotherapy remains the only realistic option for …

Purpose The mechanism of resistance to cisplatin during treatment of bladder cancer (BC)
has been a subject of intense investigation in clinical research. This study aims to identify …

Systemic therapy for muscle-invasive bladder cancer (BC) remains dominated by cisplatin-
based chemotherapy. However, resistance to cisplatin therapy greatly limits long-term …

Background Lung cancer is the leading worldwide cancer with almost 1.5 million deaths
every year. Some drugs for lung cancer treatment have been available on the market for …

Cisplatin (CDDP)-based combination chemotherapy remains the mainstream treatment for
advanced bladder cancer. However, its efficacy is often limited due to the development of …

Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a
single agent and in combination with agents commonly used in lung cancer. The ability of …